Schrodinger, Inc. (SDGR) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This summary covers Schrodinger, Inc.'s Quarterly Report on Form 10-Q for the period ended June 30, 2024. Schrodinger operates a physics-based computational platform for drug discovery and materials science, generating revenue through two primary segments: Software (licensing and services) and Drug Discovery (collaborations and proprietary programs). The company is advancing three proprietary clinical-stage programs: SGR-1505 (MALT1 inhibitor), SGR-2921 (CDC7 inhibitor), and SGR-3515 (WEE1/MYT1 inhibitor).
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | 6 Months 2024 | 6 Months 2023 |
|---|---|---|---|---|
| Total Revenue | $47,334 | $35,189 | $83,932 | $99,971 |
| Net (Loss) Income | $(54,047) | $4,278 | $(108,771) | $133,414 |
| Diluted EPS | $(0.74) | $0.06 | $(1.50) | $1.79 |
| Operating Cash Flow | — | — | $(92,999) | $(49,537) |
| Cash & Equivalents | $108,109 | — | — | — |
| Marketable Securities | $269,180 | — | — | — |
| Total Liquidity | $381.5M | — | — | — |
Note: Q2 2023 net income was driven by a significant tax benefit and non-cash gains on equity investments. Q2 2024 reflects a return to operating losses.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 35% year-over-year in Q2 2024 ($47.3M vs. $35.2M), driven by a 104% increase in Drug Discovery revenue ($11.9M vs. $5.8M) and a 21% increase in Software revenue ($35.4M vs. $29.4M). However, for the six-month period, total revenue decreased 16% due to the absence of a $147.3M gain on equity investments and large milestone payments recognized in the prior year.
- Profitability: The company reported a net loss of $54.0M in Q2 2024, compared to net income of $4.3M in Q2 2023. The prior year's income was largely non-recurring, stemming from a tax benefit and fair value adjustments on equity stakes (Nimbus, Structure Therapeutics).
- Segment Performance:
- Software: Hosted software revenue grew 82% in Q2, indicating a shift toward subscription models. On-premise revenue grew 12%.
- Drug Discovery: Revenue increased significantly due to milestone achievements and collaboration progress, offsetting the lack of large one-time distributions seen in 2023.
- Equity Investments: The company recorded a $5.8M unrealized loss on equity investments in Q2 2024 (primarily Structure Therapeutics and Morphic), contrasting with a $40.7M gain in Q2 2023.
Guidance, Outlook, and Risks
- Clinical Progress:
- SGR-1505: Phase 1 trial in B-cell lymphomas is ongoing; initial data expected H1 2025. FDA granted orphan drug designation for mantle cell lymphoma.
- SGR-2921: Phase 1 trial in acute myeloid leukemia initiated; FDA granted Fast Track designation in July 2024. Data expected H2 2025.
- SGR-3515: Phase 1 trial in advanced solid tumors initiated in Q2 2024. Data expected H2 2025.
- Liquidity: As of June 30, 2024, the company held $381.5M in cash, cash equivalents, and marketable securities. Management believes this is sufficient to fund operations for at least the next 24 months.
- Capital Raising: The company has an active At-The-Market (ATM) offering program with $241.1M remaining capacity. It raised $8.7M net proceeds under this program in the first six months of 2024.
- Risks:
- Operating Losses: The company has a history of significant losses and expects to incur losses for several years as it invests in R&D and clinical trials.
- Collaboration Dependency: Revenue from drug discovery is volatile and dependent on milestone achievements by partners (e.g., Bristol-Myers Squibb, Eli Lilly).
- Equity Valuation: Fair value of equity investments in collaborators (Morphic, Structure Therapeutics) fluctuates with market conditions, impacting non-operating income.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $381.5M liquidity position against the $93M operating cash burn in the first six months of 2024.
- Revenue Quality: Assess the proportion of revenue derived from recurring software subscriptions versus one-time collaboration milestones.
- Clinical Milestones: Monitor the timeline for initial data readouts for SGR-1505, SGR-2921, and SGR-3515 (expected 2025) as key value drivers.
- Equity Stake Valuation: Review the fair value adjustments of investments in Morphic (pending acquisition by Eli Lilly) and Structure Therapeutics, which significantly impact net income volatility.
- ATM Utilization: Track the pace of share issuance under the ATM program and its potential dilutive impact on existing shareholders.